{"id":"rara","name":"Retinoic acid receptor alpha (RARA)","symbol":"RARA","route":"/targets/rara/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9864","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131759","uniprot":"https://www.uniprot.org/uniprotkb/P10276/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P10276","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2055","open-targets":"https://platform.opentargets.org/target/ENSG00000131759","civic":"https://civicdb.org/genes/5914/summary","oncokb":"https://www.oncokb.org/gene/RARA","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RARA","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=RARA","depmap":"https://depmap.org/portal/gene/RARA?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000131759-RARA","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5914","omim":"https://www.omim.org/entry/180240"}],"products":[{"id":"acitretin","name":"Acitretin","status":"approved","modality":"Oral systemic retinoid","route":"/drugs/acitretin/"},{"id":"isotretinoin","name":"Isotretinoin","status":"approved","modality":"Oral retinoid (differentiating agent)","route":"/drugs/isotretinoin/"}],"trials":[{"id":"acns0332","name":"COG ACNS0332","nct":"NCT00392327","phase":"3","status":"mixed"},{"id":"anbl0531","name":"ANBL0531","nct":"NCT00499616","phase":"3","status":"positive"},{"id":"anbl0032","name":"COG ANBL0032","nct":"NCT00026312","phase":"3","status":"positive"},{"id":"nct02050321","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","nct":"NCT02050321","phase":"2"}],"pathways":[],"companies":[],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}